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 Abstract  
Activating mutations in either the Sonic Hedgehog (SHH) or the Wingless (WNT) signaling 
pathways gives rise to two of the major subgroups of medulloblastoma. Analysis of the gene 
expression profiles of the SHH and WNT medulloblastoma subgroups have revealed that they 
might be mutually exclusive. It is still not known, however, what the role of the WNT signaling 
pathway is in SHH-induced tumor growth. We hypothesize that constitutively activating the 
WNT signaling pathway through the inhibition of Glycogen Synthase Kinase 3 (GSK-3) will 
prevent SHH subgroup tumor growth. Cerebellar progenitors were treated with varying doses of 
CHIR-98014, a GSK-3 inhibitor, for 24 hours and collected for western blot analysis or 
immunofluorescence analysis. Wild-type cells were treated with SHH and CHIR-98014 for 24 
hours and collected for FACS analysis. A decreasing trend in proliferation marker, pRb, and 
mitosis marker, pHH3, was seen, as well as an increasing trend in S phase inhibition marker, 
CDKN1A (p21), with increasing dosages of drug in tumor cells. Treatment with CHIR-98014 in 
the presence of SHH in cells cultured from wild-type mice showed a shift in cell cycle phase 
away from S phase. To elucidate the maximum tolerable dose of CHIR-98014, oral gavage of 
wild type mice with varying dosages of CHIR-98014 was then conducted and presented no 
significant change in weight during treatment. Increasing dosages of CHIR-98014 were shown to 
significantly decrease proliferation of tumor cells, revealing possible viability for use of CHIR-
98014 targeting medulloblastoma. These findings support the hypothesis that constitutively 
activated WNT signaling through the inhibition of GSK-3 prevents SHH subgroup tumor 
growth. Understanding the role of the WNT signaling pathway in the context of SHH-induced 
medulloblastoma may lead to better management of the disease. Further characterization of 
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CHIR-98014 and its effects on cerebellar development and tumorigenesis is necessary and 
provides significance in the treatment of SHH-induced medulloblastoma. 
 
Introduction 
Current research has identified four different subgroups of medulloblastoma, each of which have 
distinct genetic abnormalities and diagnostic outcomes (Taylor, et al., 2011). Of the four 
subgroups, only two are currently associated with specific genetic mutations in known 
developmental signaling pathways: Sonic Hedgehog (SHH) and Wingless (WNT) (Skowron, 
Ramaswamy, & Taylor, 2015). The genetic alterations leading to each of the subgroups may be 
mutually exclusive, given the lack of overlap between the molecular signatures of the tumors as 
well as the distinct differences in gene expression profiles (Northcott, et al., 2017). SHH-group 
and WNT-group medulloblastomas are drastically different from one another. SHH-group 
medulloblastomas originate from cerebellar granule neuron progenitors (CGNPs), while WNT-
group medulloblastomas arise from the rhombic lip. SHH-medulloblastomas also have a 
significantly worse prognosis (Northcott, et al., 2011). Since medulloblastoma tumor cells are 
thought to develop from CGNPs in the cerebellum during development, developmental signaling 
pathways like SHH and WNT might need to be tightly regulated to prevent tumorigenesis. 
 The cerebellum, which develops in the first 2 weeks of life in mice and the 1st year of life 
in humans, also depends on SHH signaling to grow (Wechsler-Reya & Scott, 1999). CGNPs in 
the external granule layer (EGL) proliferate in response to SHH secreted by nearby neurons. 
After proliferating, CGNPs migrate into the internal granule layer (IGL) where they differentiate 
into mature granule neurons (Wechsler-Reya & Scott, 1999).  It is now well known in 
developmental biology that the SHH and WNT signaling pathways interact closely in other parts 
of the brain and body. For example, activation of CTNNB, the main transcription factor in the 
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WNT signaling pathway, by means of preventing its degradation, results in the progressive loss 
of SHH expression during the development of dopamine neurons in the ventral midbrain (vMB) 
(Tang, et al., 2010). Additionally, deletion of GSK-3, an inhibitor of the WNT signaling 
pathway, in the cortex results in hyperproliferation and increases expression of the SHH 
signaling proteins GLI1 and GLI2 (Kim, et al., 2009). It is clear from studies in the forebrain that 
a delicate balance between SHH and WNT signaling must be established during development. 
Given that the two medulloblastoma subgroups are mutually exclusive, yet the developmental 
pathways are closely interconnected, it is still not known whether the SHH medulloblastoma 
subgroup depends on the WNT signaling pathway. To explore this, we hypothesized that 
constitutively activating the WNT signaling pathway through inhibition of GSK-3 blocks SHH-
driven proliferation during cerebellar development and medulloblastoma tumor growth. 
 We decided to activate the WNT signaling pathway in mice affected by SHH-induced 
medulloblastoma to determine the effect of WNT signaling on the development of SHH-driven 
tumors. The Smoothened (Smo) proto-oncogene has been found to be a key transducer of the 
SHH pathway, so mice of the SmoM2 line were used to model SHH-induced medulloblastoma 
(Dey, et al., 2012). GSK-3 has been shown to be a master regulator in the coordination of 
progenitor proliferation and homeostasis, present in the signaling of embryonic stem cell self-
renewal, and essential in the RTK, WNT, and SHH signaling pathways (Kim, et al., 2009). These 
factors imply that GSK-3 may have an essential role in tumorigenesis of SHH subgroup 
medulloblastoma. We activated the WNT signaling pathway by inhibiting GSK-3 through the 
use of CHIR-98014 during cerebellar development and medulloblastoma tumor growth.  
 Through manipulation of the WNT signaling pathway by means of GSK-3 inhibition, the 
presence of the WNT signaling pathway as a necessity in SHH-driven tumor growth will be 
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determined. The experiments conducted elucidate which specific cellular processes are effected 
by GSK-3 inhibition, through cell marker and cell cycle analysis. We will first determine the 
maximal tolerated dose (MTD) of the GSK-3 inhibitor CHIR-98014 in wild-type mice. The 
optimal dosage determined by MTD study will be used to determine the possible effectiveness of 
CHIR-98014 in the treatment of SHH-induced medulloblastoma. The findings of these 
experiments show that inhibition of GSK-3 in tumor cells prevents tumor growth while shifting 
cells out of S phase. Oral gavage testing found that, at the dosages administered, mice did not 
show any significant changes in weight and development with CHIR-98014. 
 
Methods 
Mice 
We bred wild-type C57BL/6 mice for use in cell culture experiments. We also used the Cre-loxP 
system to produce SHH-driven medulloblastoma-prone mice. GFAP-Cre mice were bred, which 
express Cre recombinase in GFAP+ stem cells in the cerebellum, with SmoM2f/f mice to create 
GFAP-Cre;SmoM2f/wt (G-Smo) mice. All G-Smo mice formed medulloblastoma-like tumors by 
postnatal day 12 (P12). 
 
Cell Culture 
One 12-well plate was used to culture wild-type cerebellar cells derived from C57BL/6 mice. 
One 12-well plate and one 96-well plate were used to culture medulloblastoma tumor cells 
derived from SmoM2-induced G-Smo tumor mice. Cerebella and tumors were dissected at P15, 
dissociated using the Papain Dissociation Kit (Worthington Biochemical Corporation) and plated 
on their respective 12-well or 96-well plates coated with Poly-L-Lysine (Sigma #P4832). The 
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cells were then incubated for 4 hours in DMEM/F12 media (Gibco #11330-032) supplemented 
with N2, Pen/Strep, KCl, and 10% heat-inactivated fetal bovine serum (HI-FBS) in order to 
allow for cells to adjust to the new environment. Afterwards, the media was removed and 
replaced with new media that did not contain fetal bovine serum. At this time, SHH was 
introduced to wild-type plates and CHIR-98014 (SelleckChem #S2745) was introduced to select 
wells in all plates. The wild-type 12-well plate was divided into a control group, a group treated 
with SHH, and a group treated with SHH and CHIR-98014. The tumor 12-well plate was divided 
into four groups of three replicates each and administered vehicle (DMSO), 500 nM, 1μM, or 2 
μM of CHIR-98014 respectively. The 96-well plate was divided into six groups, each containing 
sixteen replicates. These six groups were vehicle, 250 nM, 500 nM, 750 nM, 1 μM, 2 μM of the 
drug respectively. The three plates were then incubated for another 24-hour period and collected. 
The wild-type 12-well plate was then collected for FACS Analysis, the tumor 12-well plate was 
collected for western blotting, and the 96-well plate was analyzed using immunofluorescence. 
 
FACS Analysis 
Cerebellar granule neuron progenitors from wild-type mice were plated on a 12-well plate as 
described above and used for FACS analysis. The thymidine analog EdU was added to cells at a 
concentration of 200 μM 1 hour prior to dissociation. Dissociated cells from each well were 
removed from the cell culture plate into round-bottomed tubes. Cells within each tube were fixed 
using a FIX & PERM Cell Permeabilization Kit (Thermo Fisher #GAS004). Replicate samples 
were then stained with FxCycle Violet Stain (Thermo Fisher #F10347), p21 Waf1/Cip1 12D1 
Rabbit mAb (CST #8587), pHH3 D2C8 (CST #3465), and EdU (Thermo Fisher #C10338). 
Samples were then resuspended in sheath fluid until run through flow cytometry. 
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Western Blot 
Western blotting was performed using the samples gathered from the 12-well plated cell cultures. 
First, the media in the plate was removed, and the tumor cells were lysed. Lysis was performed 
using a solution of 1x RIPA buffer, Na3VO4, NaF, and a protease inhibitor cocktail. The samples 
were then homogenized and the supernatant extracted from each. Protein concentrations within 
the supernatant samples were estimated using the colorimetric Pierce BCA Protein Assay Kit 
(Thermo Scientific) and analyzed on a plate reader at 595 nm. The samples were then diluted to 
maintain consistent protein concentration across. Loading buffer solution (LBS) and 
Dithiothreitol (DTT), a protein reducer, were then added to the samples. The samples were then 
boiled for 5 minutes at 80°C and loaded onto an 8-16% Mini-PROTEAN TGX Precast Protein 
Gel (Bio-Rad) to run in electrophoresis. The run buffer used during electrophoresis consisted of 
Tris, Glycine, SDS, and H2O. After electrophoresis was completed, the proteins were transferred 
from the polyacrylamide gel onto a PVDF membrane using a transfer buffer of Trizma, Glycine, 
H2O, and Methanol. PVDF membranes were stored in 1x Tris-buffered saline with Tween-20 
(TBST) until staining. Antibody staining of the membranes was conducted using the SNAP ID 
2.0 (Millipore). The membranes were stained using primary antibodies phospho-Rb (Ser807/811) 
(CST #8516S), p21 (Abcam #ab109199), and pCtnnb (Ser33/37/Thr41) (CST #9561). We used 
the secondary antibody, HRP-linked goat anti-rabbit antibody (Abcam #ab205718). The blots 
were immersed in SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific), 
which is a chemiluminescent substrate. Samples were scanned with the LI-COR C-DiGit 
Western Blot Scanner (LI-COR Biosciences) immediately after treating with the substrate. 
Images were processed and analyzed in Image Studio. 
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Immunofluorescence Staining 
Cell cultures within the 96-well plate had media removed initially and were fixed using 4% 
paraformaldehyde (PFA) during incubation for 30 minutes. Fixative was then removed, and 
Phosphate Buffered Saline (PBS) was added until staining. After removal of PBS, solutions were 
soaked in blocking buffer consisting of 5% donkey serum in 0.3% PBS with Tween-20. Once 
blocking was finished, the samples were stained with DAPI (Invitrogen #D1306) along with 
primary antibodies phospho-Rb (Ser807/811) and phospho-Histone H3 (Ser10) (6G3) (CST 
#9706L). Samples were then washed and incubated with fluorophore linked secondary antibodies 
goat anti-rabbit Alexa Fluor 488 (Thermo Scientific #A-11034) or goat anti-mouse Alexa Fluor 
555 (Thermo Scientific #A-21424). Individual cells containing successfully stained tumor cells 
were then observed and imaged using the Olympus IX83 Inverted Fluorescence Microscope and 
Olympus CellSens software. Captured images were then processed and analyzed with 
Fiji/ImageJ. 
 
Oral Gavage 
Wild-type mice were treated with CHIR-98014 in varying dosages to determine the maximum 
tolerated dose (MTD) of the drug in mice. A group of 11 mice were divided into four groups and 
administered 0 mg/kg, 15 mg/kg, 30 mg/kg, or 50 mg/kg of CHIR-98014 per body weight. Drug 
was administered in solution with sunflower seed oil and DMSO to increase solubility. Oral 
gavage in mice was started at P12 and continued for 16 days. Weights of the mice were 
periodically recorded over the administration period. 
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Results 
Cell Marker Analysis 
Preliminary characterization of CHIR-98014, namely its effects on proliferation and mitosis on 
tumors cells, must be conducted to determine viability as a treatment for medulloblastoma. To do 
so, markers for proliferation and mitosis were analyzed in western blotting and 
immunofluorescence analysis. Western blotting of the sample revealed a decreasing trend in the 
expression of the proliferating marker, pRb, across increasing dosages of CHIR-98014 (Figure 1, 
Figure 2). Intermediate dosages of CHIR-98014 at 500 nM and 1 µM concentrations resulted in 
increased raw expression of pRb in tumor cells. This increased expression was also true for the S 
phase cell cycle arrest marker, p21, in the same samples (Figure 1, Figure 2), but showed a 
sustained increase in expression in the highest concentration of CHIR-98014 when compared to 
vehicle control. 
 
 
Figure 1. Western blotting for pRb and p21 presence in tumor cells treated with increasing 
CHIR-98014 dosages. 
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Figure 2. Bar graphs of average A) pRb and B) p21 expression levels. (Veh: n=3; 500nM: 
n=3; 1µM: n=2; 2µM: n=3) Error bars represent standard error of the mean (SEM). 
 
A decreasing trend in pRb was found with increasing dosages of CHIR-98014 through 
immunofluorescence cell count analysis as well (Figure 3B-F) as compared to vehicle control 
(Figure 3A). Quantification of pRb+ cell counts showed a decrease in pRb+ cells with increasing 
doses of CHIR-98014 (Figure 4A). The cell count analysis revealed a decreasing trend in cell 
count for expression of the mitosis marker, pHH3 (Figure 4B). For both pRb and pHH3 
expression, dosages below 2 µM showed paradoxical increases in cell counts above that of the 
vehicle (Figure 3B-E, Figure 4). An increase in cell-matrixes and clumping was also observed 
through DAPI staining (Figure 3B-E). The highest dose of CHIR-98014, however, showed less 
connectivity and aggregation between cells (Figure 3F). 
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Figure 3. Immunofluorescence images demonstrating change in cell stages across CHIR-
98014 dosages. Dosages administered were A) vehicle control, B) 250 nM, C) 500 nM, D) 750 
nM, E) 1 µM, and F) 2 µM. Each condition was stained for DAPI, pHH3, and pRb. 
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Figure 4. Bar graphs of average A) pRb and B) pHH3 raw cell counts of each CHIR-98014 
dosage condition per 20x image per well. (Veh: n=9; 250 nM: n=3; 500 nM: n=7; 750 nM: 
n=6; 1µM: n=6; 2µM: n=8) Error bars represent SEM. 
 
Cell Cycle Analysis 
Although a decreasing trend in proliferation and mitosis markers were shown with increasing 
dosages of CHIR-98014 in tumor mice, the exact effect that CHIR-98014 has on cell cycle 
progression remained unclear. Flow cytometry was conducted to determine percentage of cells in 
each cell cycle phase when treated with SHH and CHIR-98014. FACS analysis of wild type cells 
cultured in the presence of SHH showed an increase in both S phase and G2-M. Samples 
exposed to both SHH and CHIR-98014 showed a decrease in S phase from SHH-treated 
samples, along with proportional increases in G1 and G2-M phases (Figure 5). Samples treated 
with increasing doses of CHIR-98014 showed decreases in EdU expression indicating 
differentiation. Representative flow cytometry plots of cell cycle distribution are shown in Figure 
6. 
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Figure 5. Cluster bar graph of average percentage of cells in each cell cycle phase across 
Vehicle, SHH, and SHH + CHIR-98014 groups treated wild type cell cultures. (Veh: n=4; 
SHH: n=2; SHH+CHIR-98014: n=4). Error bars represent SEM. 
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Figure 6. Representative flow cytometry plots of A) Vehicle, B) SHH, and C) SHH + CHIR-
98014 treated samples’ gated by cell cycle phase. Fx indicates DNA content within the cell. 
EdU indicates increase in cell proliferation. Numbers indicate percentage in each cell cycle 
phase. 
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In vivo Analysis 
After characterizing the effects that CHIR-98014 had on proliferation, mitosis, and cell cycles, 
we decided to test CHIR-98014 in vivo to determine if the GSK-3 inhibitor could be a viable 
therapy for medulloblastoma. We first administered CHIR-98014 by oral gavage to wild-type 
C57BL/6 to determine the maximal tolerated dose. Weight tracking during oral gavage revealed 
that there were no significant differences in weight gain of the mice across all administered 
dosages of drug (Figure 7). One death occurred between days 4 and 8 in the 50 mg/kg group. No 
significant changes in mouse physiology or development were observed during the oral gavage 
treatment period. Our results indicate that CHIR-98014 is not toxic to mice even at the highest 
administered dose. 
 
 
Figure 7. Average mice weight after administration of varying dosages of CHIR-98014. (0 
mg/kg: n=2; 15 mg/kg: n=3; 30 mg/kg: n=3; 50 mg/kg n=3, n=2 after day 4). 
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Discussion 
Cell Marker and Cycle Analysis 
These findings reveal that increased WNT signaling through GSK-3 inhibition negatively affects 
proliferation and cell stability of SHH-induced tumor growth. Negative trends in pRb and pHH3 
expression were shown consistently through the western blotting signal and cell count analysis in 
response to increasing doses of the GSK-3 inhibitor, CHIR-98014. In juxtaposition of this, all of 
the intermediate dosage concentrations, from 250nM to 1 µM paradoxically showed increases in 
expression in both of the markers. The p21 marker, however, showed a significant increase in 
expression above vehicle treatment across all of the doses tested. 
 The observed negative trends in western blotting signal and cell count analysis for pRb in 
tumor cells implies that GSK-3 inhibition may lead to significant blockage of proliferation at 
high dosages of CHIR-98014. Given the increase in expression with lower dosages of the drug, 
extension of research into a larger range of dosages may be beneficial. These trends are 
supported in the analysis of pHH3, another marker for proliferation and mitosis. Virtually no 
proliferation was seen among cells at the 2 µM dosage concentration. 
 p21, an S phase inhibition marker, showed an increase in expression through all dosages 
above vehicle treatment in tumor cells. These results support the assertion that cell cycle 
progression was inhibited. There seems to be a spike in protein expression at the 1 µM dosage of 
the drug, so further research into an explanation for the decrease at 2 µM may yield interesting 
findings. One possible reason for this dip in expression may be an increase in cell death, which 
was not tested. This explanation may also be the cause for the drastic decrease in pRb and pHH3 
expression and cell counts at this dosage. 
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 Cell cycle analysis of wild type cells treated with SHH and/or CHIR-98014 through 
FACS revealed that cells treated with CHIR-98014 shift away from S phase. Culturing cerebellar 
granule neuron progenitors with SHH led to an increase in S phase and G2-M phase as compared 
to cell treated with vehicle, providing further evidence for increased proliferation of cerebellar 
progenitors in the presence of SHH. Addition of CHIR-98014 to SHH treated cells showed a 
mitigation of these effects by a shift away from S phase, leading to proportional increases in 
percent in both G1 and G2-M phases. The mechanism by which this occurs, however, is still 
unclear. Upon initial analysis, no apparent increase in cell cycle arrest was shown by marker p21. 
However, the FACS data has not been fully analyzed as of yet. As SHH and CHIR-98014 were 
introduced at the same time, these results suggest that CHIR-98014 is able to overcome the 
effects of SHH and significantly reduce proliferation. 
 
Oral Gavage Implications 
The oral gavage study showed that, at the dosages administered, there were no significant 
changes in weight as the mice developed. A goal of this study was to gain direction in 
determining the MTD of the drug and we found that no administered dose of CHIR-98014 had 
adverse effects in weight gain or development of wild-type mice. One mouse of the 50 mg/kg 
group died within the first 8 days of treatment, but it is not clear whether or not this was due to 
administration of drug. The results of the oral gavage study show clear possibilities to continue 
testing GSK-3 inhibitors as a potential therapeutic, as no detrimental effects on the development 
of the mice were seen. However, further advancements regarding MTD and effects on 
development in both wild type and tumor mice must first be conducted. 
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Limitations 
The results from cell marker analysis hint at a relationship between CHIR-98014 treatment and 
inhibition of tumor growth. While we saw decreasing expression of pRb and p21 across the 
different doses, we plan to normalize against actin signal to control for protein concentration 
variation between the samples. Staining of the immunofluorescence samples had left artifacts 
and blotches in the images, which may have contributed to slight inaccuracy in cell counts for 
the staining. Immunofluorescence analysis would benefit from normalization of pRb and pHH3 
cell counts against total cell number by DAPI staining, but the clumping nature of the tumor cells 
at intermediate dosages led to unreliable total cell counts. These tumor studies through IF 
analysis would benefit from more accurate methods of cell count calculation in these samples, 
which may provide more conclusive results. We also plan to analyze markers for cell death in the 
immunofluorescence analysis. Finally, we noted a paradoxical effect in that proliferation seemed 
to starkly increase at lower dosages of the drug. The mechanism by which this dose-dependent 
effect arises has not been determined yet. 
The FACS analysis of wild type mice only yielded information regarding changes in cell 
cycle. Although the samples were stained with other antibodies, most of them had failed, leading 
to inconclusive data regarding apoptosis and the mechanism by which the cell cycle phase shift 
occurs. Further study could benefit from a redo of FACS with these markers. 
 The oral gavage study was performed as a gateway experiment to eventually lead into 
MTD determination and characterization of its effects on mouse development. The solution that 
was used to treat the mice contained sunflower seed oil and DMSO, because the drug was 
insoluble in water. These other compounds within the injected solution may have possibly 
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altered the weight and development of the mice. We were unable to determine the MTD of the 
drug, because we were unable to get drug into solution past 50 mg/kg for this study. 
 
Future Direction 
Future experiments for this research include western blotting and immunofluorescence analysis 
including wider ranges of markers. To complete a direct comparison between effects on wild-
type and tumor mice, western blotting and immunofluorescence analysis using exact cell markers 
can be performed on wild-type mice and FACS analysis can be performed on tumor mice. 
Current findings have provided information on only a small number of cellular processes that are 
affected during treatment with CHIR-98014. To gain a better characterization of the drug, 
analyses of cellular markers for DNA synthesis, apoptosis, and other cellular processes may 
prove useful. The transition to in vivo work may yield insights into the survival curve of mice, 
maximum tolerated dosages of the drug in mice, and affected cellular mechanisms in live mice 
through increasing dosages of CHIR-98014. These experiments could be the gateway to 
exploration of CHIR-98014 as an effective treatment of SHH Group medulloblastoma. 
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